Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Presentation ACC 2023

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Presenter: Christie Ballantyne

March 05, 2023

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Presentation Controversies and Advances 2018

Updateon PCS K-9 Inhibition

Presenter: P.K. Shah

November 15, 2018

Presentation EAS 2018

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Presenter: Michelle L. O’Donoghue

May 07, 2018

Presentation CDM 2017

Can Heart Disease be Eventually Abolished? The PCSK9 Revolution

Presenter: Robert A. Vogel

October 06, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

Presentation ACC 2017

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

Presenter: Marc Sabatine

March 17, 2017

Presentation AHA 2016

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

Presenter: Steven E. Nissen

November 15, 2016

Advertisement

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Updateon PCS K-9 Inhibition

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Can Heart Disease be Eventually Abolished? The PCSK9 Revolution

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content